Evidence map›Paper›PMID 39594832›Full record

ArticleCancers2024

Association of HLA-G Expression, Its Genetic Variants and Related Neuro-Immunomodulation with Characteristics of Bladder Carcinoma.

Vladimira Durmanova, Iveta Mikolaskova, Eszter Zsemlye, Agata Ocenasova, Helena Bandzuchova, Magda Suchankova, Boris Kollarik, Patrik Palacka, Milan Zvarik, Maria Bucova and 1 more

Abstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Association ofInternational journal of molecular sciences · 2026
    Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Vladimira DurmanovaInstitute of Immunology, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia.
Iveta MikolaskovaInstitute of Immunology, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia.ORCID 0000-0003-4443-9069
Eszter ZsemlyeInstitute of Immunology, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia.
Agata OcenasovaInstitute of Immunology, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia.ORCID 0009-0002-4397-5310
Helena BandzuchovaNational Transplant Organisation, 831 01 Bratislava, Slovakia.
Magda SuchankovaInstitute of Immunology, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia.
Boris KollarikDepartment of Urology, Saints Cyril and Methodius Hospital, University Hospital Bratislava, 851 07 Bratislava, Slovakia.
Patrik Palacka2nd Department of Oncology, Faculty of Medicine and National Cancer Institute, Comenius University, Klenova 1, 833 10 Bratislava, Slovakia.ORCID 0000-0003-4505-0952
Milan ZvarikDepartment of Nuclear Physics and Biophysics, Faculty of Mathematics, Physics and Computer Science, Comenius University in Bratislava, 842 48 Bratislava, Slovakia.ORCID 0000-0002-0165-6066
Maria BucovaInstitute of Immunology, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia.
Luba HunakovaInstitute of Immunology, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia.ORCID 0000-0003-2159-0807

Funding

the Scientific Grant Agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic and Slovak Academy of Sciences VEGA 1/0090/22the Slovak Research and Development Agency APVV-22-0231
6 · The paper itself

Abstract

backgroundHuman leukocyte antigen G (HLA-G) is an immune checkpoint molecule with immunosuppressive and anti-inflammatory activities. It belongs to class I non-classical major histocompatibility complex molecules and has been upregulated in various cancer types. In bladder cancer (BC) tumors, the association of HLA-G with cancer progression has to be explained.

methodsA total of 89 BC patients and 74 control subjects were genotyped for the HLA-G 14 bp ins/del polymorphism. In urine cell samples, HLA-G mRNA expression was analyzed using real-time PCR. Soluble HLA-G (sHLA-G) serum levels were measured by ELISA. The associations between the HLA-G 14 bp ins/del polymorphism, HLA-G mRNA expression, and/or sHLA-G levels and selected variables including tumor grade, disease stage, body mass index, and heart rate variability (HRV) parameters were evaluated.

resultsThe protective HLA-G 14 bp ins/ins genotype under the recessive genetic model was associated with lower HLA-G mRNA expression in the BC group (

conclusionsOur results suggest the impact of the HLA-G 14 bp ins/del variant, HLA-G expression, and autonomic nervous system imbalance on advanced stages of BC.

Indexed as

bladder cancerheart rate variability (HRV)HLA-GinflammationmRNA expression

Identifiers

PMID39594832
PMCPMC11593171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.